Spruce Biosciences Inc (SPRB)

$56.67 +0.27 (0.48%)
Market Cap 77.40M
Revenue (ttm) 0.00
Net Income (ttm) -38.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 36,200
Avg Vol 63,332
Day's Range N/A - N/A
Shares Out 1.37M
Stochastic %K 44%
Beta 3.26
Analysts Strong Sell
Price Target $186.60

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 343 5986
Address:
611 Gateway Boulevard, Suite 740, South San Francisco, United States
Stock_Catcher
Stock_Catcher May. 12 at 1:48 AM
Treasure Tuesday Watchlist Pt.7 $NVTS $SPRB $SATL $MNTS $PMAX Crazy Runners Today , Let's Find More Tomorrow
0 · Reply
OMNIFALL
OMNIFALL May. 12 at 12:48 AM
$SPRB definitely dont do more than a 1/2 size position because its a 50-50 on whether they get a crl and raise 40m at $20/share
0 · Reply
Zdxss1
Zdxss1 May. 10 at 3:35 PM
$SPRB It’s important to frame BTD correctly: this is not just an “achievement,” it’s an entitlement earned by the drug. The designation comes because the therapy has already demonstrated strong evidence and a professional regulatory path. In other words, BTD is a recognition of merit — the drug deserves it based on the data and mechanism. That’s why the market often anticipates it in advance: investors see the science, understand the trajectory, and expect the designation as part of a professional process. The announcement is more of a formal confirmation than a surprise milestone.
0 · Reply
W2Cap
W2Cap May. 10 at 9:31 AM
$CMMB $SPRB I don't disagree. We have a 12m market cap, low float. SPRB trades at 50 dollars but 'only' a $150 million market cap - tiny still in bio terms. No other treatment; and I'm going to hazard a guess a similar market size (I know SPRB is for a rare disease with zero treatment). I'm just an impatient one. And want them to execute the partnership asap.
0 · Reply
dkmadhvn
dkmadhvn May. 1 at 2:16 PM
$SPRB Have they announced ER date
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 30 at 2:05 PM
$SGMO May prove to be another case like $SPRB coming back from the dead ... But very risky one
1 · Reply
Bill_S_Preston_San_Dimas
Bill_S_Preston_San_Dimas Apr. 28 at 6:43 PM
$SPRB in at $54
0 · Reply
albertoaguinaga
albertoaguinaga Apr. 27 at 7:19 PM
$SPRB
0 · Reply
notreload_ai
notreload_ai Apr. 27 at 4:53 PM
Craig-Hallum initiated coverage on $SPRB with a Buy rating and $140 price target. TA-ERT advances toward accelerated approval for MPS IIIB in 2026. https://notreload.xyz/xy/craig-hallum-initiates-strong-buy-on-spruce-biosciences-as-ta-ert-advances-toward-approval/
0 · Reply
BioPM1989
BioPM1989 Apr. 26 at 12:59 PM
$SPRB It was just small position Was right call, others are lucky idiots I'm still up for the year Management lied! Quadrupled down! Plan all along Markets are irrational Nobody could have predicted that I exited beforehand On to next idea, mom knows I'm special
1 · Reply
Latest News on SPRB
Spruce Biosciences appoints Brian Walls as VP, market access

2026-05-04T12:21:00.000Z - 9 days ago

Spruce Biosciences appoints Brian Walls as VP, market access

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

May 4, 2026, 8:00 AM EDT - 9 days ago

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy

2026-04-27T14:10:40.000Z - 15 days ago

Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy

DNLI

Spruce Biosciences initiated with a Buy at Craig-Hallum

2026-04-27T12:11:23.000Z - 16 days ago

Spruce Biosciences initiated with a Buy at Craig-Hallum

Spruce Biosciences 1.15M share Spot Secondary priced at $50.00

2026-04-21T11:08:06.000Z - 22 days ago

Spruce Biosciences 1.15M share Spot Secondary priced at $50.00

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Apr 20, 2026, 11:45 PM EDT - 22 days ago

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences down 13% at $60.50 after equity offering announcement

2026-04-20T20:52:59.000Z - 22 days ago

Spruce Biosciences down 13% at $60.50 after equity offering announcement

Spruce Biosciences announces common stock offering, no amount given

2026-04-20T20:07:29.000Z - 22 days ago

Spruce Biosciences announces common stock offering, no amount given

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Apr 20, 2026, 4:01 PM EDT - 22 days ago

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 12:30 PM EDT - 2 months ago

Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026

Spruce Biosciences price target lowered to $170 from $180 at Citizens

2026-03-10T09:40:19.000Z - 2 months ago

Spruce Biosciences price target lowered to $170 from $180 at Citizens

Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 11:20 AM EDT - 2 months ago

Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026

Spruce Biosciences appoints Dale Hooks as chief commercial officer

2026-03-09T11:28:43.000Z - 2 months ago

Spruce Biosciences appoints Dale Hooks as chief commercial officer

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Mar 9, 2026, 7:05 AM EDT - 2 months ago

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Mar 2, 2026, 4:05 PM EST - 2 months ago

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 3:20 PM EST - 2 months ago

Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Biotech Alert: Searches spiking for these stocks today

2026-02-19T17:07:02.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

Spruce Biosciences price target lowered to $200 from $220 at H.C. Wainwright

2026-02-19T11:11:51.000Z - 2 months ago

Spruce Biosciences price target lowered to $200 from $220 at H.C. Wainwright

Spruce Biosciences provides update on Type B tralesinidase meetings with FDA

2026-02-18T13:01:20.000Z - 2 months ago

Spruce Biosciences provides update on Type B tralesinidase meetings with FDA

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Feb 18, 2026, 7:00 AM EST - 3 months ago

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 4:05 PM EST - 3 months ago

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Feb 5, 2026, 4:05 PM EST - 3 months ago

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Feb 3, 2026, 8:00 AM EST - 3 months ago

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Jan 28, 2026, 8:00 AM EST - 3 months ago

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Harbour BioMet acquires common stock in Spruce Biosciences

2026-01-19T20:10:14.000Z - 4 months ago

Harbour BioMet acquires common stock in Spruce Biosciences

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Jan 18, 2026, 7:02 PM EST - 4 months ago

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Jan 8, 2026, 8:00 AM EST - 4 months ago

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls

2025-12-23T14:35:25.000Z - 5 months ago

Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls

AARD AME ATAI BC BRO COTY CWAN

Spruce Biosciences initiated with an Outperform at Oppenheimer

2025-12-23T11:30:37.000Z - 5 months ago

Spruce Biosciences initiated with an Outperform at Oppenheimer

BMRN

Spruce Biosciences assumed with a Buy at H.C. Wainwright

2025-12-22T11:10:33.000Z - 5 months ago

Spruce Biosciences assumed with a Buy at H.C. Wainwright

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Dec 15, 2025, 8:00 AM EST - 5 months ago

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 6 months ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 7, 2025, 9:44 AM EDT - 7 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Sep 15, 2025, 7:00 AM EDT - 8 months ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Stock_Catcher
Stock_Catcher May. 12 at 1:48 AM
Treasure Tuesday Watchlist Pt.7 $NVTS $SPRB $SATL $MNTS $PMAX Crazy Runners Today , Let's Find More Tomorrow
0 · Reply
OMNIFALL
OMNIFALL May. 12 at 12:48 AM
$SPRB definitely dont do more than a 1/2 size position because its a 50-50 on whether they get a crl and raise 40m at $20/share
0 · Reply
Zdxss1
Zdxss1 May. 10 at 3:35 PM
$SPRB It’s important to frame BTD correctly: this is not just an “achievement,” it’s an entitlement earned by the drug. The designation comes because the therapy has already demonstrated strong evidence and a professional regulatory path. In other words, BTD is a recognition of merit — the drug deserves it based on the data and mechanism. That’s why the market often anticipates it in advance: investors see the science, understand the trajectory, and expect the designation as part of a professional process. The announcement is more of a formal confirmation than a surprise milestone.
0 · Reply
W2Cap
W2Cap May. 10 at 9:31 AM
$CMMB $SPRB I don't disagree. We have a 12m market cap, low float. SPRB trades at 50 dollars but 'only' a $150 million market cap - tiny still in bio terms. No other treatment; and I'm going to hazard a guess a similar market size (I know SPRB is for a rare disease with zero treatment). I'm just an impatient one. And want them to execute the partnership asap.
0 · Reply
dkmadhvn
dkmadhvn May. 1 at 2:16 PM
$SPRB Have they announced ER date
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 30 at 2:05 PM
$SGMO May prove to be another case like $SPRB coming back from the dead ... But very risky one
1 · Reply
Bill_S_Preston_San_Dimas
Bill_S_Preston_San_Dimas Apr. 28 at 6:43 PM
$SPRB in at $54
0 · Reply
albertoaguinaga
albertoaguinaga Apr. 27 at 7:19 PM
$SPRB
0 · Reply
notreload_ai
notreload_ai Apr. 27 at 4:53 PM
Craig-Hallum initiated coverage on $SPRB with a Buy rating and $140 price target. TA-ERT advances toward accelerated approval for MPS IIIB in 2026. https://notreload.xyz/xy/craig-hallum-initiates-strong-buy-on-spruce-biosciences-as-ta-ert-advances-toward-approval/
0 · Reply
BioPM1989
BioPM1989 Apr. 26 at 12:59 PM
$SPRB It was just small position Was right call, others are lucky idiots I'm still up for the year Management lied! Quadrupled down! Plan all along Markets are irrational Nobody could have predicted that I exited beforehand On to next idea, mom knows I'm special
1 · Reply
Stockhunter008
Stockhunter008 Apr. 24 at 3:50 AM
$CMMB $SPRB Compare CMMB's BTD prospects to those of SPRB prior to their BTD grant
0 · Reply
Roaring_Capybara
Roaring_Capybara Apr. 22 at 5:35 PM
$SPRB Merck takeover: https://maandhunter.substack.com/p/inbx-the-keytruda-defense-play-just
1 · Reply
parbv
parbv Apr. 22 at 2:02 PM
$SPRB My issue is how do you trust management to not do another garbage raise that screws shareholders. I've been modeling the PRV as being worth 150 million, but they'll probably sell it for 25 instead
2 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Apr. 22 at 3:28 AM
Did you intentionally cut off the last line of Shkreli's twitter $SPRB convo? In the last line, which you left out, shkreli gives $SPRB a price target of $225/share (see my screenshot below, which includes the part you left out). Shkreli's new price target for sprb is a FOUR BAGGER. So, sprb at 52\share is a SCREAMING BUY. Shizz is gonna run so hard over next few weeks.
1 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Apr. 22 at 3:00 AM
@ShakeThatMoneyMaker Nice try. You’re posting total nonsense. Give us an actual model. What’s your model? You’re just going wave your hands. You won’t give us a model bc any honest model shows that $SPRB at 52/share is massively undervalued.
0 · Reply
ShakeThatMoneyMaker
ShakeThatMoneyMaker Apr. 22 at 2:32 AM
$SPRB dilution kills all bios.
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Apr. 22 at 1:34 AM
At $52/share $SPRB, I’m all in. 1. The voucher alone is worth 57/share. 2. They now have 48/share in cash. 3. The asset is worth anywhere from 118/share (absolute worst case) to 236/share. Add that up. $SPRB is worth at least 223/share, if not 341/share. 52/share is a screaming buy. Stock will be up 50% in next 90 days. At least.
2 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Apr. 22 at 1:18 AM
$SPRB
0 · Reply
Jakcofalltrades
Jakcofalltrades Apr. 21 at 11:28 PM
$SPRB this junk is going to $25 soon
0 · Reply
strategicmind
strategicmind Apr. 21 at 11:08 PM
$SPRB thank you BioMarin for this asset! Even with the dillution, market cap of a billion is good estimate doing a DCF. Which roughly implies 6X from these prices 😉. I’ll take even half that
0 · Reply
strategicmind
strategicmind Apr. 21 at 9:26 PM
$SPRB Bought some. Very good risk/ reward ratio here IMO. Voucher alone is worth 2X more than market cap right now.
0 · Reply
thedavidsonny
thedavidsonny Apr. 21 at 9:01 PM
$SPRB HOPEFULLY IT RECOVERS 😢 PLAN B CTNT ON 🔥 ... GET MONEY BACK
0 · Reply